Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Other Financing Activities

Financing cash flows not reported separately.

Coherus Oncology, Inc.NASDAQ: CHRS

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities declines year over year

Q1 FY2026 other financing activities of $60K (cash outflow) fell 77.3% year over year, ahead of the -241.1% change in trailing-twelve-month other financing activities. Over 3 fiscal years it compounded at +191.9% a year.

Context

  • Other financing activities amounted to 115.6% of revenue in FY2025, up 102.5 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -77.3% holds above the trailing-twelve-month pace of -241.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$60K-372.7% QoQ
Last fiscal yearDec 2025
-$48.77M-239.4% YoY
LTMMar 2026
-$48.56M-241.1% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-77.3%——
1 year-239.4%——
3-year CAGR+191.9%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(48.77M) USD
Year-over-year change
-239.4%

Other Financing Activities vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 other financing activities of $48.56M is the largest of the 11 companies compared; the peer median is $246K.
  • Its year-over-year change of -241.1% is the 10th highest of 11, against a peer median of -99.0%.
  • Other financing activities amounts to 103.6% of revenue for CHRS, versus a peer median of 1.7%.
CHRS Competitors Peer median
Other Financing Activities for CHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$48.56M -241.1%+191.9%103.6%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$1.42M -42.0%+149.9%4.1%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$1.29M -98.9%—2184.7%
OABIOmniAb, Inc.LTM Mar 2026$709K -106.8%—2.5%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$461K +631.7%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026$328K -40.9%-9.5%0.9%
TARAProtara Therapeutics, Inc.LTM Mar 2026$272K -107.7%——
IVVDInvivyd, Inc.LTM Mar 2026$220K -460.7%—0.4%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$153K -93.1%—0.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$74K -99.0%-46.5%3.8%
CDXSCodexis, Inc.LTM Mar 2026$3K -100.0%—0.0%
Peer median (excluding CHRS) $246K-99.0%-9.5%1.7%

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(287.1M)(291.75M)(237.89M)28.51M168.02M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
Deferred Income Tax9.44M0000
Stock-Based Compensation51.36M50.74M43.11M27.8M16.97M
Change in Working Capital42.36M(79.26M)(36.83M)55.89M(5.84M)
Accounts Receivables34.06M13.05M(150.68M)149.35M93.56M
Inventory(6.25M)(47.35M)(46.73M)(31.95M)(17.11M)
Accounts Payables874K(4.55M)23.76M(3.94M)(19.56M)
Other Working Capital13.68M(40.41M)136.83M(57.57M)(62.74M)
Other Non-Cash Items143.05M75.45M52.93M(137.92M)(321.59M)
Operating Cash Flow(37.43M)(241.12M)(174.88M)(20.44M)(138.51M)
Capital Expenditures(1.29M)(2.04M)(286K)00
Acquisitions (Net)1.29M0845K00
Purchases of Investments(182.49M)(127.38M)(19.51M)0(103.84M)
Sales of Investments181.36M0157.64M14.89M21.46M
Other Investing Activities(137.29M)(37.43M)5.95M215.43M457.46M
Investing Cash Flow(138.41M)(166.85M)144.64M230.32M375.09M
Debt Repayment(672K)49.93M0(223.41M)(233.19M)
Common Stock Issued40.9M6.36M74.22M1.46M8.25M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities54.3M(1.96M)(4.62M)34.98M(48.77M)
Financing Cash Flow51.88M54.33M69.6M(186.97M)(273.71M)
Effect of Forex Changes00(12K)00
Net Change in Cash(123.96M)(353.65M)39.34M22.91M(37.13M)
Free Cash Flow(38.72M)(243.16M)(175.17M)(20.44M)(138.51M)

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.